Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

[Identification of a novel CYP2C9 gene mutation (1400T>C) and assessment of its enzymatic activity in vitro].

Dai DP, Li CB, Wang SH, Geng PW, Hu GX, Cai JP.

Zhonghua Yi Xue Za Zhi. 2013 Nov 26;93(44):3537-41. Chinese.

PMID:
24521898
2.

Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient.

Luo SB, Li CB, Dai DP, Wang SH, Wang ZH, Geng PW, Cai J, Jiang ZL, Pu CW, Shang K, Yuan XM, Cao YP, Hu GX, Cai JP.

J Pharmacol Sci. 2014;125(2):150-6.

PMID:
25075423
3.

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Liang R, Li L, Li C, Gao Y, Liu W, Hu D, Sun Y.

J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7.

PMID:
22528326
4.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

5.

Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.

Di Fusco D, Ciccacci C, Rufini S, Forte V, Novelli G, Borgiani P.

Thromb Res. 2013 Jul;132(1):123-6. doi: 10.1016/j.thromres.2013.05.002. Epub 2013 May 30.

PMID:
23726967
6.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.

7.

Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient.

Dai DP, Li CB, Wang SH, Cai J, Geng PW, Zhou YF, Hu GX, Cai JP.

Pharmacogenomics. 2015;16(13):1475-86. doi: 10.2217/pgs.15.89. Epub 2015 Aug 10.

PMID:
26255664
8.

In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.

Dai DP, Wang YH, Wang SH, Geng PW, Hu LM, Hu GX, Cai JP.

Acta Pharmacol Sin. 2013 Nov;34(11):1449-56. doi: 10.1038/aps.2013.123. Epub 2013 Sep 30.

9.

In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.

Dai DP, Wang SH, Geng PW, Hu GX, Cai JP.

Basic Clin Pharmacol Toxicol. 2014 Apr;114(4):305-10. doi: 10.1111/bcpt.12159. Epub 2013 Nov 8.

10.

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Scott SA, Edelmann L, Kornreich R, Desnick RJ.

Am J Hum Genet. 2008 Feb;82(2):495-500. doi: 10.1016/j.ajhg.2007.10.002. Epub 2008 Jan 17.

11.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
12.

Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.

Natarajan S, Ponde CK, Rajani RM, Jijina F, Gursahani R, Dhairyawan PP, Ashavaid TF.

Pharmacol Rep. 2013;65(5):1375-82.

13.

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Molden E, Okkenhaug C, Ekker Solberg E.

Eur J Clin Pharmacol. 2010 May;66(5):525-30. doi: 10.1007/s00228-010-0813-6. Epub 2010 Mar 31.

PMID:
20354686
14.

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.

Tomek A, Maťoška V, Kolářová T, Neumann J, Srámek M, Sarbochová I, Táborský L, Bojar M, Goetz P, Serebruany VL.

Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12.

PMID:
23774101
15.

Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.

Esmerian MO, Mitri Z, Habbal MZ, Geryess E, Zaatari G, Alam S, Skouri HN, Mahfouz RA, Taher A, Zgheib NK.

J Clin Pharmacol. 2011 Oct;51(10):1418-28. doi: 10.1177/0091270010382910. Epub 2010 Dec 8.

PMID:
21148049
16.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
17.

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.

O'Brien TJ, Kidd RS, Richard CA, Ha NH, Witcher P, Tran LV, Barbour A, Tuck M, McIntosh SD, Douglas JN, Harralson AF.

Clin Chim Acta. 2013 Sep 23;424:73-5. doi: 10.1016/j.cca.2013.05.008. Epub 2013 May 17.

PMID:
23688605
18.

Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese.

Zeng WT, Zheng QS, Huang M, Cen HJ, Lai Y, Chen WY, Zhao LZ, Leng XY.

Pharmazie. 2012 Jan;67(1):69-73.

PMID:
22393834
19.

Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.

Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S.

Eur J Pharmacol. 2013 Jun 15;710(1-3):80-4. doi: 10.1016/j.ejphar.2013.04.006. Epub 2013 Apr 16.

PMID:
23602689
20.

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.

Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, Tai SS.

BMC Med Genet. 2011 Jun 6;12:80. doi: 10.1186/1471-2350-12-80.

Items per page

Supplemental Content

Write to the Help Desk